-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, UfAGDs2bVnlgwdgmFdoEGDA8DZ4QWCP+r1OXZfQRpLTA4TMkZp1enu68vOTT+09c LN9BTFDvu/oezuXCizY/FA== 0001238916-07-000004.txt : 20070702 0001238916-07-000004.hdr.sgml : 20070702 20070702173525 ACCESSION NUMBER: 0001238916-07-000004 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070629 FILED AS OF DATE: 20070702 DATE AS OF CHANGE: 20070702 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BIOSITE INC CENTRAL INDEX KEY: 0000834306 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 330288606 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 11030 ROSELLE ST CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6194554808 MAIL ADDRESS: STREET 1: 11030 ROSELLE ST CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: BIOSITE DIAGNOSTICS INC DATE OF NAME CHANGE: 19960710 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BUECHLER KENNETH F CENTRAL INDEX KEY: 0001238916 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21873 FILM NUMBER: 07956641 BUSINESS ADDRESS: STREET 1: C/O BIOSITE INC STREET 2: 11030 ROSELLE STREET CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 8584554808 4 1 edgardoc.xml PRIMARY DOCUMENT X0202 4 2007-06-29 0 0000834306 BIOSITE INC BSTE 0001238916 BUECHLER KENNETH F BIOSITE INCORPORATED 9975 SUMMERS RIDGE ROAD SAN DIEGO CA 92121 0 1 0 1 President & Chief Scientific O President & Chief Scientific O Common Stock 2007-06-29 4 U 0 58 92.5 D 0 D Incentive Stock Option (right to buy) 13.875 2007-06-29 4 D 0 10 0 D 2008-05-21 Common Stock 10 0 D Incentive Stock Option (right to buy) 24.95 2007-06-29 4 D 0 4008 0 D 2012-06-18 Common Stock 4008 0 D Incentive Stock Option (right to buy) 31.625 2007-06-29 4 D 0 3726 0 D 2010-06-02 Common Stock 3726 0 D Incentive Stock Option (right to buy) 41.56 2007-06-29 4 D 0 2406 0 D 2011-06-14 Common Stock 2406 0 D Incentive Stock Option (right to buy) 44.18 2007-06-29 4 D 0 2263 0 D 2014-06-18 Common Stock 2263 0 D Incentive Stock Option (right to buy) 47.66 2007-06-29 4 D 0 2098 0 D 2013-06-18 Common Stock 2098 0 D Incentive Stock Option (right to buy) 53.38 2007-06-29 4 D 0 1873 0 D 2015-06-17 Common Stock 1873 0 D Non-Qualified Stock Option (right to buy) 24.95 2007-06-29 4 D 0 23878 0 D 2012-06-18 Common Stock 23878 0 D Non-Qualified Stock Option (right to buy) 31.625 2007-06-29 4 D 0 71274 0 D 2010-06-02 Common Stock 71274 0 D Non-Qualified Stock Option (right to buy) 41.56 2007-06-29 4 D 0 72594 0 D 2011-06-14 Common Stock 72594 0 D Non-Qualified Stock Option (right to buy) 44.18 2007-06-29 4 D 0 32737 0 D 2014-06-18 Common Stock 32737 0 D Non-Qualified Stock Option (right to buy) 47.66 2007-06-29 4 D 0 77902 0 D 2013-06-18 Common Stock 77902 0 D Non-Qualified Stock Option (right to buy) 49.15 2007-06-29 4 D 0 15000 0 D 2014-10-22 Common Stock 15000 0 D Non-Qualified Stock Option (right to buy) 53.38 2007-06-29 4 D 0 53127 0 D 2015-06-17 Common Stock 53127 0 D This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $786 representing the difference between the exercise price of the option and $92.50, the merger consideration ($78.63 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $270,740 representing the difference between the exercise price of the option and $92.50, the merger consideration ($67.55 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $226,820 representing the difference between the exercise price of the option and $92.50, the merger consideration ($60.88 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $122,562 representing the difference between the exercise price of the option and $92.50, the merger consideration ($50.94 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $109,348 representing the difference between the exercise price of the option and $92.50, the merger consideration ($48.32 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $94,074 representing the difference between the exercise price of the option and $92.50, the merger consideration ($44.84 per share). This option, which provided for vesting in sixteen equal quarterly installments over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $73,272 representing the difference between the exercise price of the option and $92.50, the merger consideration ($39.12 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $1,606,204representing the difference between the exercise price of the option and $92.50, the merger consideration ($67.55 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $4,338,805 representing the difference between the exercise price of the option and $92.50, the merger consideration ($60.88 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $3,697,938 representing the difference between the exercise price of the option and $92.50, the merger consideration ($50.94 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $1,581,852 representing the difference between the exercise price of the option and $92.50, the merger consideration ($39.12 per share). This option, which provided for daily vesting over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $3,493,126 representing the difference between the exercise price of the option and $92.50, the merger consideration ($44.84 per share). This option, which provided for vesting in sixteen equal quarterly installments over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $650,250 representing the difference between the exercise price of the option and $92.50, the merger consideration ($43.35 per share). This option, which provided for vesting in sixteen equal quarterly installments over a four-year period commencing on the date of grant, was canceled by Inverness Medical Innovations ("Inverness") pursuant to a merger agreement between the Issuer and Inverness in exchange for a cash payment of $2,078,328 representing the difference between the exercise price of the option and $92.50, the merger consideration ($39.12 per share). End of period holdings reflects 58 shares purchased in connection with the Company's ESPP plan on 6/28/07. By: Robyn Shutak For: Kenneth Buechler 2007-07-02 -----END PRIVACY-ENHANCED MESSAGE-----